{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T20:17:54Z","timestamp":1793305074691,"version":"4.5.0"},"reference-count":124,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,9,5]],"date-time":"2018-09-05T00:00:00Z","timestamp":1536105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"DOI":"10.13039\/501100001677","name":"Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001677","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ANR MRFOCUS","award":["ANR-15-CE14-0032-02"],"award-info":[{"award-number":["ANR-15-CE14-0032-02"]}]},{"name":"Fight-HF Avenir investment program","award":["ANR-15-RHUS-0004"],"award-info":[{"award-number":["ANR-15-RHUS-0004"]}]},{"name":"Ile de France CORRDIM"},{"name":"ARDoC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,10,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Activation of the mineralocorticoid receptor (MR) in the distal nephron by its ligand, aldosterone, plays an important role in sodium reabsorption and blood pressure regulation. However, expression of the MR goes beyond the kidney. It is expressed in a variety of other tissues in which its activation could lead to tissue injury. Indeed, MR activation in the cardiovascular (CV) system has been shown to promote hypertension, fibrosis, and inflammation. Pharmacological blockade of the MR has protective effects in several animal models of CV disease. Furthermore, the use of MR antagonists is beneficial for heart failure patients, preventing mortality and morbidity. A better understanding of the implications of the MR in the setting of CV diseases is critical for refining treatments and improving patient care. The mechanisms involved in the deleterious effects of MR activation are complex and include oxidative stress, inflammation, and fibrosis. This review will discuss the pathological role of the MR in the CV system and the major mechanisms underlying it.<\/jats:p>","DOI":"10.1093\/ajh\/hpy120","type":"journal-article","created":{"date-parts":[[2018,8,30]],"date-time":"2018-08-30T00:34:27Z","timestamp":1535589267000},"page":"1165-1174","source":"Crossref","is-referenced-by-count":132,"title":["Mineralocorticoid Receptor and Cardiovascular Disease"],"prefix":"10.1093","volume":"31","author":[{"given":"Mathieu","family":"Buonafine","sequence":"first","affiliation":[{"name":"INSERM, UMRS, Centre de Recherche des Cordeliers, Sorbonne University, Paris, France"},{"name":"Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Bonnard","sequence":"additional","affiliation":[{"name":"INSERM, UMRS, Centre de Recherche des Cordeliers, Sorbonne University, Paris, France"},{"name":"Paris Descartes University, Paris, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Jaisser","sequence":"additional","affiliation":[{"name":"INSERM, UMRS, Centre de Recherche des Cordeliers, Sorbonne University, Paris, France"},{"name":"Paris Descartes University, Paris, France"},{"name":"INSERM, Clinical Investigation Centre, French-Clinical Research Infrastructure Network (F-CRIN) INI-CRCT, RHU Fight-HF, Nancy, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,9,5]]},"reference":[{"key":"2022111617185743800_CIT0001","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1152\/physrev.00011.2014","article-title":"Epithelial sodium transport and its control by aldosterone: the story of our internal environment revisited","volume":"95","author":"Rossier","year":"2015","journal-title":"Physiol Rev"},{"key":"2022111617185743800_CIT0002","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1124\/pr.115.011106","article-title":"Emerging roles of the mineralocorticoid receptor in pathology: toward new paradigms in clinical pharmacology","volume":"68","author":"Jaisser","year":"2016","journal-title":"Pharmacol Rev"},{"key":"2022111617185743800_CIT0003","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1161\/01.CIR.0000153800.09920.40","article-title":"Mineralocorticoid receptor inhibition ameliorates the transition to myocardial failure and decreases oxidative stress and inflammation in mice with chronic pressure overload","volume":"111","author":"Kuster","year":"2005","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0004","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"2022111617185743800_CIT0005","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1056\/NEJMoa030207","article-title":"Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction","volume":"348","author":"Pitt","year":"2003","journal-title":"N Engl J Med"},{"key":"2022111617185743800_CIT0006","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"2022111617185743800_CIT0007","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1161\/HYPERTENSIONAHA.112.198986","article-title":"Aldosterone-specific activation of cardiomyocyte mineralocorticoid receptor in vivo","volume":"61","author":"Messaoudi","year":"2013","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0008","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1161\/CIRCULATIONAHA.106.653964","article-title":"Complementary and incremental mortality risk prediction by cortisol and aldosterone in chronic heart failure","volume":"115","author":"G\u00fcder","year":"2007","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0009","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1161\/HYPERTENSIONAHA.109.148783","article-title":"Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase \u00bd mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways","volume":"55","author":"Krug","year":"2010","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0010","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/01.RES.0000159937.05502.d1","article-title":"Angiotensin II and aldosterone regulate gene transcription via functional mineralocortocoid receptors in human coronary artery smooth muscle cells","volume":"96","author":"Jaffe","year":"2005","journal-title":"Circ Res"},{"key":"2022111617185743800_CIT0011","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1161\/HYPERTENSIONAHA.114.04981","article-title":"Adipocyte mineralocorticoid receptor activation leads to metabolic syndrome and induction of prostaglandin D2 synthase","volume":"66","author":"Urbanet","year":"2015","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0012","doi-asserted-by":"crossref","first-page":"5363","DOI":"10.1210\/en.2006-0944","article-title":"Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus","volume":"147","author":"Guo","year":"2006","journal-title":"Endocrinology"},{"key":"2022111617185743800_CIT0013","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1161\/HYPERTENSIONAHA.111.185520","article-title":"Oxidative stress causes mineralocorticoid receptor activation in rat cardiomyocytes: role of small GTPase Rac1","volume":"59","author":"Nagase","year":"2012","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0014","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.jsbmb.2014.04.015","article-title":"Post-translational modifications of the mineralocorticoid receptor: how to dress the receptor according to the circumstances","volume":"143","author":"Faresse","year":"2014","journal-title":"J Steroid Biochem Mol Biol"},{"key":"2022111617185743800_CIT0015","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/j.mce.2011.06.025","article-title":"Molecular pharmacology of the mineralocorticoid receptor: prospects for novel therapeutics","volume":"350","author":"Kolkhof","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2022111617185743800_CIT0016","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.ahj.2017.03.011","article-title":"True rate of mineralocorticoid receptor antagonists-related hyperkalemia in placebo-controlled trials: a meta-analysis","volume":"188","author":"Vukadinovi\u0107","year":"2017","journal-title":"Am Heart J"},{"key":"2022111617185743800_CIT0017","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1161\/CIRCHEARTFAILURE.113.000792","article-title":"Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF)","volume":"7","author":"Rossignol","year":"2014","journal-title":"Circ Heart Fail"},{"key":"2022111617185743800_CIT0018","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1002\/ejhf.688","article-title":"Impact of eplerenone on cardiovascular outcomes in heart failure patients with hypokalaemia","volume":"19","author":"Rossignol","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"2022111617185743800_CIT0019","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1517\/13543776.2014.854772","article-title":"Mineralocorticoid receptor modulators: a patent review (2007\u20132012)","volume":"24","author":"Collin","year":"2014","journal-title":"Expert Opin Ther Pat"},{"key":"2022111617185743800_CIT0020","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1093\/eurheartj\/eht235","article-title":"The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects","volume":"34","author":"Bauersachs","year":"2013","journal-title":"Eur Heart J"},{"key":"2022111617185743800_CIT0021","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"2022111617185743800_CIT0022","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"2022111617185743800_CIT0023","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.1016\/j.nephro.2017.02.003","article-title":"Renin-angiotensin system blockade: finerenone","volume":"13","author":"Ruilope","year":"2017","journal-title":"Nephrol Ther"},{"key":"2022111617185743800_CIT0024","first-page":"893","article-title":"Mineralocorticoid excess, dietary sodium, and myocardial fibrosis","volume":"120","author":"Brilla","year":"1992","journal-title":"J Lab Clin Med"},{"key":"2022111617185743800_CIT0025","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1161\/HYPERTENSIONAHA.115.06709","article-title":"Vascular smooth muscle mineralocorticoid receptor contributes to coronary and left ventricular dysfunction after myocardial infarction","volume":"67","author":"Gueret","year":"2016","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0026","doi-asserted-by":"crossref","first-page":"R946","DOI":"10.1152\/ajpregu.00402.2006","article-title":"Elevated cardiac tissue level of aldosterone and mineralocorticoid receptor in diastolic heart failure: beneficial effects of mineralocorticoid receptor blocker","volume":"292","author":"Ohtani","year":"2007","journal-title":"Am J Physiol Regul Integr Comp Physiol"},{"key":"2022111617185743800_CIT0027","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1161\/HYPERTENSIONAHA.108.117531","article-title":"Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling","volume":"52","author":"Di Zhang","year":"2008","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0028","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"2022111617185743800_CIT0029","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0030","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1001\/jamainternmed.2018.0850","article-title":"Aldosterone antagonist therapy and mortality in patients with ST-segment elevation myocardial infarction without heart failure: a systematic review and meta-analysis","volume":"178","author":"Dahal","year":"2018","journal-title":"JAMA Intern Med"},{"key":"2022111617185743800_CIT0031","doi-asserted-by":"crossref","first-page":"236","DOI":"10.2337\/db14-0670","article-title":"Mineralocorticoid receptor blockade improves coronary microvascular function in individuals with type 2 diabetes","volume":"64","author":"Garg","year":"2015","journal-title":"Diabetes"},{"key":"2022111617185743800_CIT0032","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1210\/jc.2007-0393","article-title":"Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus","volume":"92","author":"Joffe","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"key":"2022111617185743800_CIT0033","doi-asserted-by":"crossref","first-page":"769","DOI":"10.47102\/annals-acadmedsg.Hurkan","article-title":"Spironolactone does not prevent restenosis after coronary stenting in humans","volume":"33","author":"Kursaklioglu","year":"2004","journal-title":"Ann Acad Med Singapore"},{"key":"2022111617185743800_CIT0034","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.cardiores.2005.05.009","article-title":"Aldosterone increases T-type calcium channel expression and in vitro beating frequency in neonatal rat cardiomyocytes","volume":"67","author":"Lalev\u00e9e","year":"2005","journal-title":"Cardiovasc Res"},{"key":"2022111617185743800_CIT0035","doi-asserted-by":"crossref","first-page":"3025","DOI":"10.1161\/CIRCULATIONAHA.104.503706","article-title":"Conditional mineralocorticoid receptor expression in the heart leads to life-threatening arrhythmias","volume":"111","author":"Ouvrard-Pascaud","year":"2005","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0036","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3317\/jraas.2006.005","article-title":"Beneficial effect of eplerenone on cardiac remodelling and electrical properties of the failing heart","volume":"7","author":"De Mello","year":"2006","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"2022111617185743800_CIT0037","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/CIRCRESAHA.108.184044","article-title":"Gap junction remodeling and spironolactone-dependent reverse remodeling in the hypertrophied heart","volume":"104","author":"Qu","year":"2009","journal-title":"Circ Res"},{"key":"2022111617185743800_CIT0038","doi-asserted-by":"crossref","first-page":"H310","DOI":"10.1152\/ajpheart.01137.2009","article-title":"Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model","volume":"299","author":"Stein","year":"2010","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022111617185743800_CIT0039","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","article-title":"The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation","volume":"289","author":"Lavall","year":"2014","journal-title":"J Biol Chem"},{"key":"2022111617185743800_CIT0040","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/hr.2010.277","article-title":"Role of mineralocorticoid receptor on atrial structural remodeling and inducibility of atrial fibrillation in hypertensive rats","volume":"34","author":"Kimura","year":"2011","journal-title":"Hypertens Res"},{"key":"2022111617185743800_CIT0041","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1097\/FJC.0b013e31822a78c1","article-title":"Spironolactone prevents the inducibility of ventricular tachyarrhythmia in rats with aldosteronism","volume":"58","author":"Deshmukh","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"key":"2022111617185743800_CIT0042","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","article-title":"Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism","volume":"45","author":"Milliez","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"2022111617185743800_CIT0043","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1016\/S0002-9149(01)01905-1","article-title":"Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation","volume":"88","author":"Goette","year":"2001","journal-title":"Am J Cardiol"},{"key":"2022111617185743800_CIT0044","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jacc.2009.09.045","article-title":"Increased expression of mineralocorticoid receptor in human atrial fibrillation and a cellular model of atrial fibrillation","volume":"55","author":"Tsai","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"2022111617185743800_CIT0045","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1002\/clc.20689","article-title":"Increased expression of mineralocorticoid receptor and 11beta-hydroxysteroid dehydrogenase type 2 in human atria during atrial fibrillation","volume":"33","author":"De-An","year":"2010","journal-title":"Clin Cardiol"},{"key":"2022111617185743800_CIT0046","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.ijcard.2015.05.167","article-title":"Spironolactone is associated with reduced risk of new-onset atrial fibrillation in patients receiving renal replacement therapy","volume":"202","author":"Chung","year":"2016","journal-title":"Int J Cardiol"},{"key":"2022111617185743800_CIT0047","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00392-014-0754-7","article-title":"Effectiveness of aldosterone antagonists for preventing atrial fibrillation after cardiac surgery in patients with systolic heart failure: a retrospective study","volume":"104","author":"Simopoulos","year":"2015","journal-title":"Clin Res Cardiol"},{"key":"2022111617185743800_CIT0048","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1002\/clc.20914","article-title":"Effect of spironolactone on patients with atrial fibrillation and structural heart disease","volume":"34","author":"Williams","year":"2011","journal-title":"Clin Cardiol"},{"key":"2022111617185743800_CIT0049","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1002\/clc.20762","article-title":"The effect of aldosterone antagonists for ventricular arrhythmia: a meta-analysis","volume":"33","author":"Wei","year":"2010","journal-title":"Clin Cardiol"},{"key":"2022111617185743800_CIT0050","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.ijcard.2011.11.076","article-title":"Early mineralocorticoid receptor blockade in primary percutaneous coronary intervention for ST-elevation myocardial infarction is associated with a reduction of life-threatening ventricular arrhythmia","volume":"167","author":"Beygui","year":"2013","journal-title":"Int J Cardiol"},{"key":"2022111617185743800_CIT0051","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1093\/eurheartj\/ehu164","article-title":"Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study","volume":"35","author":"Montalescot","year":"2014","journal-title":"Eur Heart J"},{"key":"2022111617185743800_CIT0052","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00392-017-1157-3","article-title":"Effect of eplerenone on extracellular cardiac matrix biomarkers in patients with acute ST-elevation myocardial infarction without heart failure: insights from the randomized double-blind REMINDER Study","volume":"107","author":"Ferreira","year":"2018","journal-title":"Clin Res Cardiol"},{"key":"2022111617185743800_CIT0053","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1016\/j.jacc.2016.02.033","article-title":"Early aldosterone blockade in acute myocardial infarction: the ALBATROSS randomized clinical trial","volume":"67","author":"Beygui","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022111617185743800_CIT0054","doi-asserted-by":"crossref","DOI":"10.1136\/heartjnl-2018-312950","article-title":"Individual participant data analysis of two trials on aldosterone blockade in myocardial infarction","author":"Beygui","year":"2018","journal-title":"Heart"},{"key":"2022111617185743800_CIT0055","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s00210-014-1048-3","article-title":"Spironolactone improves endothelial dysfunction in streptozotocin-induced diabetic rats","volume":"387","author":"Adel","year":"2014","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"2022111617185743800_CIT0056","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1093\/eurheartj\/eht095","article-title":"Endothelial mineralocorticoid receptor activation mediates endothelial dysfunction in diet-induced obesity","volume":"34","author":"Sch\u00e4fer","year":"2013","journal-title":"Eur Heart J"},{"key":"2022111617185743800_CIT0057","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1161\/HYPERTENSIONAHA.107.093450","article-title":"Mineralocorticoid receptor blockade improves vasomotor dysfunction and vascular oxidative stress early after myocardial infarction","volume":"50","author":"Sart\u00f3rio","year":"2007","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0058","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1161\/01.CIR.0000039328.33137.6C","article-title":"Increased carotid wall elastic modulus and fibronectin in aldosterone-salt-treated rats: effects of eplerenone","volume":"106","author":"Lacolley","year":"2002","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0059","doi-asserted-by":"crossref","first-page":"e49","DOI":"10.1161\/CIRCRESAHA.117.312451","article-title":"Specific activation of the alternative cardiac promoter of Cacna1c by the mineralocorticoid receptor","volume":"122","author":"Mesquita","year":"2018","journal-title":"Circ Res"},{"key":"2022111617185743800_CIT0060","doi-asserted-by":"crossref","first-page":"e88942","DOI":"10.1172\/jci.insight.88942","article-title":"Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging","volume":"1","author":"DuPont","year":"2016","journal-title":"JCI Insight"},{"key":"2022111617185743800_CIT0061","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1161\/HYPERTENSIONAHA.114.03348","article-title":"Endothelial sodium channels trigger endothelial salt sensitivity with aging","volume":"64","author":"Paar","year":"2014","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0062","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1161\/CIRCRESAHA.115.308269","article-title":"Endothelial mineralocorticoid receptor mediates diet-induced aortic stiffness in females","volume":"118","author":"Jia","year":"2016","journal-title":"Circ Res"},{"key":"2022111617185743800_CIT0063","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/JOE-17-0009","article-title":"30 YEARS OF THE MINERALOCORTICOID RECEPTOR: the role of the mineralocorticoid receptor in the vasculature","volume":"234","author":"DuPont","year":"2017","journal-title":"J Endocrinol"},{"key":"2022111617185743800_CIT0064","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.116.07418","article-title":"Vascular mineralocorticoid receptors: linking risk factors, hypertension, and heart disease","volume":"68","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0065","doi-asserted-by":"crossref","first-page":"e0184888","DOI":"10.1371\/journal.pone.0184888","article-title":"The novel mineralocorticoid receptor antagonist finerenone attenuates neointima formation after vascular injury","volume":"12","author":"Dutzmann","year":"2017","journal-title":"PLoS One"},{"key":"2022111617185743800_CIT0066","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/clpt.2011.227","article-title":"Mineralocorticoid receptor blocker eplerenone improves endothelial function and inhibits Rho-associated kinase activity in patients with hypertension","volume":"91","author":"Fujimura","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2022111617185743800_CIT0067","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/ki.2011.505","article-title":"Aldosterone blockade and the mineralocorticoid receptor in the management of chronic kidney disease: current concepts and emerging treatment paradigms","volume":"81","author":"Shavit","year":"2012","journal-title":"Kidney Int"},{"key":"2022111617185743800_CIT0068","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.2215\/CJN.09421209","article-title":"A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients","volume":"5","author":"Vukusich","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"2022111617185743800_CIT0069","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1042\/CS20130050","article-title":"Mineralocorticoid receptors and the heart, multiple cell types and multiple mechanisms: a focus on the cardiomyocyte","volume":"125","author":"Bienvenu","year":"2013","journal-title":"Clin Sci (Lond)"},{"key":"2022111617185743800_CIT0070","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1161\/HYPERTENSIONAHA.112.203158","article-title":"Cardiomyocyte mineralocorticoid receptors are essential for deoxycorticosterone\/salt-mediated inflammation and cardiac fibrosis","volume":"60","author":"Rickard","year":"2012","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0071","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0072","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","article-title":"Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function","volume":"57","author":"Lother","year":"2011","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0073","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1038\/nm.2891","article-title":"Direct regulation of blood pressure by smooth muscle cell mineralocorticoid receptors","volume":"18","author":"McCurley","year":"2012","journal-title":"Nat Med"},{"key":"2022111617185743800_CIT0074","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1161\/HYPERTENSIONAHA.113.01967","article-title":"Smooth muscle cell mineralocorticoid receptors are mandatory for aldosterone-salt to induce vascular stiffness","volume":"63","author":"Galmiche","year":"2014","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0075","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.115.06530","article-title":"Deoxycorticosterone acetate\/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure","volume":"67","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0076","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1093\/cvr\/cvx097","article-title":"The role of mineralocorticoid receptor signaling in the cross-talk between adipose tissue and the vascular wall","volume":"113","author":"Jia","year":"2017","journal-title":"Cardiovasc Res"},{"key":"2022111617185743800_CIT0077","doi-asserted-by":"crossref","first-page":"e007675","DOI":"10.1161\/JAHA.117.007675","article-title":"Sex-specific mechanisms of resistance vessel endothelial dysfunction induced by cardiometabolic risk factors","volume":"7","author":"Davel","year":"2018","journal-title":"J Am Heart Assoc"},{"key":"2022111617185743800_CIT0078","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.ijcard.2017.01.013","article-title":"Essential role of ICAM-1 in aldosterone-induced atherosclerosis","volume":"232","author":"Marzolla","year":"2017","journal-title":"Int J Cardiol"},{"key":"2022111617185743800_CIT0079","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.2337\/db15-1627","article-title":"Adipocyte-specific mineralocorticoid receptor overexpression in mice is associated with metabolic syndrome and vascular dysfunction: role of redox-sensitive PKG-1 and rho kinase","volume":"65","author":"Nguyen Dinh Cat","year":"2016","journal-title":"Diabetes"},{"key":"2022111617185743800_CIT0080","first-page":"271","article-title":"What is oxidative stress","volume":"45","author":"Yoshikawa","year":"2002","journal-title":"Japan Medical Association Journal"},{"key":"2022111617185743800_CIT0081","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.freeradbiomed.2012.05.011","article-title":"Aldosterone, oxidative stress, and NF-\u03baB activation in hypertension-related cardiovascular and renal diseases","volume":"53","author":"Queisser","year":"2012","journal-title":"Free Radic Biol Med"},{"key":"2022111617185743800_CIT0082","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0029-1243253","article-title":"Aldosterone causes DNA strand breaks and chromosomal damage in renal cells, which are prevented by mineralocorticoid receptor antagonists","volume":"42","author":"Schupp","year":"2010","journal-title":"Horm Metab Res"},{"key":"2022111617185743800_CIT0083","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1681\/ASN.2014121216","article-title":"Sulfenic acid modification of endothelin B receptor is responsible for the benefit of a nonsteroidal mineralocorticoid receptor antagonist in renal ischemia","volume":"27","author":"Barrera-Chimal","year":"2016","journal-title":"J Am Soc Nephrol"},{"key":"2022111617185743800_CIT0084","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1161\/01.HYP.0000176236.55322.18","article-title":"Aldosterone stimulates matrix metalloproteinases and reactive oxygen species in adult rat ventricular cardiomyocytes","volume":"46","author":"Rude","year":"2005","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0085","doi-asserted-by":"crossref","first-page":"e12242","DOI":"10.1111\/1755-5922.12242","article-title":"The role of spironolactone on myocardial oxidative stress in rat model of streptozotocin-induced diabetes","volume":"35","author":"Mayyas","year":"2017","journal-title":"Cardiovasc Ther"},{"key":"2022111617185743800_CIT0086","doi-asserted-by":"crossref","first-page":"7542","DOI":"10.1074\/jbc.M116.764449","article-title":"Rac1 GTPase regulates 11\u03b2 hydroxysteroid dehydrogenase type 2 and fibrotic remodeling","volume":"292","author":"Lavall","year":"2017","journal-title":"J Biol Chem"},{"key":"2022111617185743800_CIT0087","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1161\/HYPERTENSIONAHA.115.06054","article-title":"Rac1-mediated activation of mineralocorticoid receptor in pressure overload-induced cardiac injury","volume":"67","author":"Ayuzawa","year":"2016","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0088","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1159\/000350539","article-title":"Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study","volume":"37","author":"Ojeda-Cervantes","year":"2013","journal-title":"Am J Nephrol"},{"key":"2022111617185743800_CIT0089","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1097\/HJH.0000000000000284","article-title":"Oxidative stress in patients affected by primary aldosteronism","volume":"32","author":"Petramala","year":"2014","journal-title":"J Hypertens"},{"key":"2022111617185743800_CIT0090","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1161\/CIRCULATIONAHA.112.097832","article-title":"Immune cell modulation of cardiac remodeling","volume":"125","author":"Mortensen","year":"2012","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0091","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.cjca.2012.06.009","article-title":"The immune system: role in hypertension","volume":"29","author":"Schiffrin","year":"2013","journal-title":"Can J Cardiol"},{"key":"2022111617185743800_CIT0092","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1038\/nri3800","article-title":"Role of innate and adaptive immune mechanisms in cardiac injury and repair","volume":"15","author":"Epelman","year":"2015","journal-title":"Nat Rev Immunol"},{"key":"2022111617185743800_CIT0093","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","article-title":"Aldosterone and inflammation","volume":"17","author":"Gilbert","year":"2010","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"2022111617185743800_CIT0094","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.steroids.2014.04.005","article-title":"Mineralocorticoid receptors in immune cells: emerging role in cardiovascular disease","volume":"91","author":"Bene","year":"2014","journal-title":"Steroids"},{"key":"2022111617185743800_CIT0095","doi-asserted-by":"crossref","first-page":"191","DOI":"10.4049\/jimmunol.0802886","article-title":"Aldosterone promotes autoimmune damage by enhancing Th17-mediated immunity","volume":"184","author":"Herrada","year":"2010","journal-title":"J Immunol"},{"key":"2022111617185743800_CIT0096","doi-asserted-by":"crossref","first-page":"H1802","DOI":"10.1152\/ajpheart.01096.2001","article-title":"Aldosterone induces a vascular inflammatory phenotype in the rat heart","volume":"283","author":"Rocha","year":"2002","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022111617185743800_CIT0097","doi-asserted-by":"crossref","first-page":"e0145946","DOI":"10.1371\/journal.pone.0145946","article-title":"Aldosterone induces renal fibrosis and inflammatory M1-macrophage subtype via mineralocorticoid receptor in rats","volume":"11","author":"Mart\u00edn-Fern\u00e1ndez","year":"2016","journal-title":"PLoS ONE"},{"key":"2022111617185743800_CIT0098","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"},{"key":"2022111617185743800_CIT0099","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1074\/jbc.M116.739243","article-title":"Mineralocorticoid receptor deficiency in macrophages inhibits atherosclerosis by affecting foam cell formation and efferocytosis","volume":"292","author":"Shen","year":"2017","journal-title":"J Biol Chem"},{"key":"2022111617185743800_CIT0100","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/en.2016-1040","article-title":"Cardiac tissue injury and remodeling is dependent upon MR regulation of activation pathways in cardiac tissue macrophages","volume":"157","author":"Shen","year":"2016","journal-title":"Endocrinology"},{"key":"2022111617185743800_CIT0101","doi-asserted-by":"crossref","first-page":"e110950","DOI":"10.1371\/journal.pone.0110950","article-title":"Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice","volume":"9","author":"Li","year":"2014","journal-title":"PLoS ONE"},{"key":"2022111617185743800_CIT0102","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1161\/CIRCRESAHA.116.310480","article-title":"T-cell mineralocorticoid receptor controls blood pressure by regulating interferon-gamma","volume":"120","author":"Sun","year":"2017","journal-title":"Circ Res"},{"key":"2022111617185743800_CIT0103","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1161\/HYPERTENSIONAHA.117.09070","article-title":"Mineralocorticoid receptor deficiency in T cells attenuates pressure overload-induced cardiac hypertrophy and dysfunction through modulating T-cell activation","volume":"70","author":"Li","year":"2017","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0104","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1161\/HYPERTENSIONAHA.113.02883","article-title":"Spironolactone decreases DOCA-salt-induced organ damage by blocking the activation of T helper 17 and the downregulation of regulatory T lymphocytes","volume":"63","author":"Amador","year":"2014","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0105","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1161\/CIRCRESAHA.115.306565","article-title":"Cardiac fibrosis: the fibroblast awakens","volume":"118","author":"Travers","year":"2016","journal-title":"Circ Res"},{"key":"2022111617185743800_CIT0106","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1161\/HYPERTENSIONAHA.114.04488","article-title":"Mineralocorticoid receptor activation and mineralocorticoid receptor antagonist treatment in cardiac and renal diseases","volume":"65","author":"Bauersachs","year":"2015","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0107","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.mce.2011.09.008","article-title":"Mechanisms of mineralocorticoid salt-induced hypertension and cardiac fibrosis","volume":"350","author":"Young","year":"2012","journal-title":"Mol Cell Endocrinol"},{"key":"2022111617185743800_CIT0108","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1042\/CS20070123","article-title":"Aldosterone and end-organ damage","volume":"113","author":"Marney","year":"2007","journal-title":"Clin Sci (Lond)"},{"key":"2022111617185743800_CIT0109","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1161\/01.HYP.24.1.30","article-title":"Increased cardiac types I and III collagen mRNAs in aldosterone-salt hypertension","volume":"24","author":"Robert","year":"1994","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0110","doi-asserted-by":"crossref","first-page":"S35","DOI":"10.1007\/BF00180074","article-title":"Renin-angiotensin system and myocardial collagen matrix remodeling in hypertensive heart disease: in vivo and in vitro studies on collagen matrix regulation","volume":"71","author":"Brilla","year":"1993","journal-title":"Clin Investig"},{"key":"2022111617185743800_CIT0111","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1161\/HYPERTENSIONAHA.107.100941","article-title":"Immediate mineralocorticoid receptor blockade improves myocardial infarct healing by modulation of the inflammatory response","volume":"51","author":"Fraccarollo","year":"2008","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0112","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1161\/01.CIR.0000142858.44680.27","article-title":"Cardiac specific increase in aldosterone production induces coronary dysfunction in aldosterone synthase-transgenic mice","volume":"110","author":"Garnier","year":"2004","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0113","doi-asserted-by":"crossref","first-page":"F1178","DOI":"10.1152\/ajprenal.00386.2003","article-title":"Chronic hyperaldosteronism in a transgenic mouse model fails to induce cardiac remodeling and fibrosis under a normal-salt diet","volume":"286","author":"Wang","year":"2004","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022111617185743800_CIT0114","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jchf.2014.08.002","article-title":"The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries","volume":"3","author":"Calvier","year":"2015","journal-title":"JACC Heart Fail"},{"key":"2022111617185743800_CIT0115","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1161\/CIRCULATIONAHA.108.809194","article-title":"Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study","volume":"119","author":"Iraqi","year":"2009","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0116","doi-asserted-by":"crossref","first-page":"5229","DOI":"10.1016\/j.ijcard.2013.08.027","article-title":"Myocardial fibrosis and QTc are reduced following treatment with spironolactone or amiloride in stroke survivors: a randomised placebo-controlled cross-over trial","volume":"168","author":"Wong","year":"2013","journal-title":"Int J Cardiol"},{"key":"2022111617185743800_CIT0117","doi-asserted-by":"crossref","first-page":"F628","DOI":"10.1152\/ajprenal.00524.2007","article-title":"Eplerenone potentiates the antiproteinuric effects of enalapril in experimental nephrotic syndrome","volume":"294","author":"Nakhoul","year":"2008","journal-title":"Am J Physiol Renal Physiol"},{"key":"2022111617185743800_CIT0118","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1111\/liv.12794","article-title":"Beneficial effects of mineralocorticoid receptor blockade in experimental non-alcoholic steatohepatitis","volume":"35","author":"Pizarro","year":"2015","journal-title":"Liver Int"},{"key":"2022111617185743800_CIT0119","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1161\/CIRCULATIONAHA.113.007690","article-title":"Upregulation of steroidogenic acute regulatory protein by hypoxia stimulates aldosterone synthesis in pulmonary artery endothelial cells to promote pulmonary vascular fibrosis","volume":"130","author":"Maron","year":"2014","journal-title":"Circulation"},{"key":"2022111617185743800_CIT0120","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1038\/jid.2010.155","article-title":"Aldosterone and mineralocorticoid receptor antagonists modulate elastin and collagen deposition in human skin","volume":"130","author":"Mitts","year":"2010","journal-title":"J Invest Dermatol"},{"key":"2022111617185743800_CIT0121","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/s11883-017-0646-1","article-title":"The role of inflammation in cardiovascular outcome","volume":"19","author":"Montecucco","year":"2017","journal-title":"Curr Atheroscler Rep"},{"key":"2022111617185743800_CIT0122","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1161\/HYPERTENSIONAHA.111.187872","article-title":"Neutrophil gelatinase-associated lipocalin is a novel mineralocorticoid target in the cardiovascular system","volume":"59","author":"Latouche","year":"2012","journal-title":"Hypertension"},{"key":"2022111617185743800_CIT0123","doi-asserted-by":"crossref","first-page":"H2372","DOI":"10.1152\/ajpheart.00283.2011","article-title":"A role for cardiotrophin-1 in myocardial remodeling induced by aldosterone","volume":"301","author":"L\u00f3pez-Andr\u00e9s","year":"2011","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"2022111617185743800_CIT0124","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1161\/HYPERTENSIONAHA.115.05431","article-title":"Neutrophil gelatinase-associated lipocalin, a novel mineralocorticoid biotarget, mediates vascular profibrotic effects of mineralocorticoids","volume":"66","author":"Tarjus","year":"2015","journal-title":"Hypertension"}],"container-title":["American Journal of Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/11\/1165\/47083789\/ajh_31_11_1165.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajh\/article-pdf\/31\/11\/1165\/47083789\/ajh_31_11_1165.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,9]],"date-time":"2024-07-09T15:10:21Z","timestamp":1720537821000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajh\/article\/31\/11\/1165\/5091253"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,5]]},"references-count":124,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,9,5]]},"published-print":{"date-parts":[[2018,10,15]]}},"URL":"https:\/\/doi.org\/10.1093\/ajh\/hpy120","relation":{},"ISSN":["0895-7061","1941-7225"],"issn-type":[{"value":"0895-7061","type":"print"},{"value":"1941-7225","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,11]]},"published":{"date-parts":[[2018,9,5]]}}}